Can we withdraw treatment in post-menopausal osteoporosis? Save

Analysis of French claims data, found over half of women initiating oral bisphosphonates (BP) between 2015 and 2020 discontinued treatment for at least one year, which was associated with a 12% increase in fracture risk. While not recommended, 42.5% of women initiating Dmab discontinued treatment for at least one year, which almost doubled their fracture risk. No increased risk was observed for long term discontinuation of IV BP.

These new data are from a case-control cohort study of over 128,000 women included in the French national claim database. The main aim was to estimate the incidence of long-term discontinuation of bisphosphonates – either oral or intravenous formulations – and denosumab among women with post-menopausal osteoporosis. A secondary aim was to compare the risk of fragility fractures in women with long-term discontinuation with the risk in women continuing treatment.

Overall, 55.1%, 68.9%, and 42.5% of women prescribed oral bisphosphonates, intravenous bisphosphonates, or denosumab had at least one long-term discontinuation recorded. These discontinuations typically happened in a woman’s mid- to late 70s, and after a mean treatment duration of 3.7–4.8 years. Crucially, when analysed by calendar year there was an upward trend in the incidence of long-term discontinuations, increasing from 1.6–17.6% in 2015 to 12.1–29.5% in 2020.

Compared with continuous treatment, long-term discontinuation increased the risk of fragility fracture by 12.4% and 92.3% for those stopping bisphosphonates or denosumab, respectively. This increased risk was observed for almost all fracture sites, with the exception of fractures in the distal forearm in women taking oral bisphosphonates. The highest increase was seen in hip fractures, with increases of 19.0% and 108.3% among women with long-term discontinuation of bisphosphonates or denosumab, respectively. No significant differences were seen between women with long-term discontinuation versus continuous treatment of intravenous bisphosphonates. The trends in occurrence of fragility fracture did not change when death was included as a competing event.

These findings are important for several reasons. Firstly, while discontinuation of denosumab is not recommended, 42.5% of women in the study stopped denosumab for at least 1 year, with a resultant doubling of fracture risk. Furthermore, the increased fracture risk observed after treatment discontinuation differed for oral versus intravenous bisphosphonates. This may warrant further investigation and clarification in the guidelines to ensure optimal management of women with post-menopausal osteoporosis in routine clinical practice.

Laborey M, et al. Risk of fragility fracture after long-term discontinuation of osteoporosis treatment in post-menopausal osteoporosis women in France: a population-based study conducted on the nationwide claim database (SNDS). Presented at EULAR 2024; OP0035.